Garcia-Bournissen F, Rokach B, Karaskov T, Koren G
G Koren, The Motherisk Program, Division of Clinical Pharmacology and Toxicology, Hospital for Sick Children, University of Toronto, 555 University Avenue, 8th Floor, Black Wing, Toronto, Canada ON, USA.
Arch Dis Child Fetal Neonatal Ed. 2007 Sep;92(5):F351-5. doi: 10.1136/adc.2006.100156. Epub 2006 Oct 31.
Methamphetamine misuse is a serious health problem of epidemic proportions. Use of this drug, particularly during pregnancy, is difficult to ascertain. Sparse information is available on gestational exposure.
To quantify methamphetamine accumulation in hair, identify the use of methamphetamine with other drugs of abuse and characterise correlations between concentrations of methamphetamine in maternal and neonatal hair.
Motherisk laboratory at the Hospital for Sick Children routinely carries out analysis of methamphetamine in hair. Mothers and infants with positive results for methamphetamine in hair were identified. Drugs present in hair were analysed by ELISA and positive results were confirmed by gas chromatgraphy/mass spectrometry.
396 people positive for methamphetamine in their hair were identified from our database. Almost 85% of them were positive for at least one other drug of abuse, mostly cocaine. Eleven mother-baby pairs with hair positive for methamphetamine were identified. Methamphetamine levels in hair ranged between 0.13 and 51.97 ng/mg in the mothers and between 0 and 22.73 ng/mg in the neonates. Methamphetamine levels in mothers and neonates correlated significantly. One (9%) neonate was negative for methamphetamine even though the mother was positive.
To our knowledge, this is the first report on fetal exposure to methamphetamine during pregnancy, showing transplacental transfer of the drug, with accumulation in fetal hair. Hair measurement for methamphetamine in neonates is a useful screening method to detect intra-uterine exposure to the drug. The data also indicate that positive exposure to methamphetamine strongly suggests that the person is a polydrug user, which may have important implications for fetal safety.
甲基苯丙胺滥用是一个具有流行规模的严重健康问题。这种药物的使用情况,尤其是在孕期的使用情况,很难确定。关于孕期接触该药物的信息稀少。
量化甲基苯丙胺在毛发中的蓄积量,确定甲基苯丙胺与其他滥用药物的联合使用情况,并描述母体和新生儿毛发中甲基苯丙胺浓度之间的相关性。
病童医院的Motherisk实验室常规开展毛发中甲基苯丙胺的分析。确定毛发中甲基苯丙胺检测结果呈阳性的母亲和婴儿。通过酶联免疫吸附测定法(ELISA)分析毛发中存在的药物,阳性结果通过气相色谱/质谱法确认。
从我们的数据库中确定了396名毛发中甲基苯丙胺检测呈阳性的人员。其中近85%至少对一种其他滥用药物检测呈阳性,大多数为可卡因。确定了11对母婴毛发中甲基苯丙胺检测呈阳性。母亲毛发中甲基苯丙胺水平在0.13至51.97纳克/毫克之间,新生儿毛发中甲基苯丙胺水平在0至22.73纳克/毫克之间。母亲和新生儿毛发中的甲基苯丙胺水平显著相关。尽管母亲检测呈阳性,但有一名(9%)新生儿甲基苯丙胺检测呈阴性。
据我们所知,这是关于孕期胎儿接触甲基苯丙胺的首份报告,显示该药物可经胎盘转运,并在胎儿毛发中蓄积。检测新生儿毛发中的甲基苯丙胺是检测子宫内药物暴露的有用筛查方法。数据还表明,甲基苯丙胺阳性暴露强烈提示该人是多种药物使用者,这可能对胎儿安全具有重要意义。